In the past, β-catenin signaling in the bone marrow has been attributed to several physiological and pathological conditions, ranging from maintenance of hematopoietic stem cells (HSCs), progression of drug-resistant mixed lineage leukemia (MLL) and formation of myeloproliferative neoplasms (MPNs) [23,24]. Here, KMT2A is linked to myeloproliferative neoplasm.